Foghorn Therapeutics Inc. (FHTX) Misses Q1 EPS by 1c

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q1 EPS of ($0.29), $0.01 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $3.26 million versus the consensus estimate of $9.35 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• S&P Global US Services PMI (Jun P) 51.3 vs 51.1 Expected
• AST SpaceMobile plans August launch of three more BlueBird satellites